satavaptan
Small moleculeexperimental
Satavaptan (INN; developmental code name SR121463, former tentative brand name Aquilda) is a vasopressin V2 receptor antagonist which was investigation by Sanofi-Aventis and was under development for the treatment of hyponatremia. It was also being studied for the treatment of ascites. Development was discontinued in 2009. — Wikipedia
Clinical trial activity
11 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
11
Phase 3
7
Phase 4
0
Earliest trial started Jun 1, 2001 (NCT00032734)
Timeline
Indications
Mechanism of action
- Vasopressin V2 receptorANTAGONIST
AVPR2 antagonist
Application for marketing approval in the EU withdrawn, compound Discontinueddue to safety concerns.
Chemistry & pharmacology
Loading structure…
SMILES
CCOc1ccc2c(c1)[C@]1(CC[C@H](CCN3CCOCC3)CC1)C(=O)N2S(=O)(=O)c1ccc(C(=O)NC(C)(C)C)cc1OC- Mol. weight
- 627.8 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSatavaptan ↗
- ChEMBLCHEMBL2107777 ↗
Also known as
- 1-(4-(n-tert-butylcarbamoyl)-2-methoxybenzenesulfonyl)-5-ethoxy-3-spiro-(4-(2-morpholinoethoxy)cyclohexane)indol-2-one fumarate
- 1-(4-(n-tert-butylcarbamoyl)-2-methoxybenzenesulfonyl)-5-ethoxy-3-spiro(4-(2-morpholinoethoxy)cyclohexane)indoline-2-one, phosphate monohydrate cis-isomer
- satavaptan
- satavaptan
- satavaptan
- satavaptan
- sr-121463
- sr-121463
- sr-121463
- sr 121463a
- sr-121463a
- sr-121463a
- sr121463b
- sr121463b
- sr121463b
- sr-121463b
- sr-121463b
- sr-121463b
- sr-121463f
- sr-121463f
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00728091 | Phase 3 | Jul 1, 2008 | Sanofi |
| NCT00366795 | Phase 3 | Aug 1, 2006 | Sanofi |
| NCT00359437 | Phase 3 | Jul 1, 2006 | Sanofi |
| NCT00358878 | Phase 3 | Jul 1, 2006 | Sanofi |
| NCT00264914 | Phase 3 | Jul 1, 2005 | Sanofi |
| NCT00274326 | Phase 3 | May 1, 2005 | Sanofi |
| NCT00264927 | Phase 3 | May 1, 2004 | Sanofi |
| NCT00501384 | Phase 2 | Apr 1, 2004 | Sanofi |
| NCT00501566 | Phase 2 | Apr 1, 2004 | Sanofi |
| NCT00501722 | Phase 2 | Apr 1, 2004 | Sanofi |
| NCT00032734 | Phase 2 | Jun 1, 2001 | Sanofi |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 11 | 11 | 2 | 2001 |
1 organizations
Page 1 / 1